Gufic BioSciences Ltd
Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.
- Market Cap ₹ 3,248 Cr.
- Current Price ₹ 324
- High / Low ₹ 504 / 285
- Stock P/E 52.5
- Book Value ₹ 59.9
- Dividend Yield 0.03 %
- ROCE 13.2 %
- ROE 12.3 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 5.40 times its book value
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 807 | 820 | 841 | |
| 657 | 684 | 708 | |
| Operating Profit | 150 | 136 | 132 | 
| OPM % | 19% | 17% | 16% | 
| -0 | 4 | 3 | |
| Interest | 17 | 25 | 28 | 
| Depreciation | 17 | 21 | 24 | 
| Profit before tax | 116 | 94 | 83 | 
| Tax % | 26% | 26% | |
| 86 | 70 | 62 | |
| EPS in Rs | 8.59 | 6.95 | 6.17 | 
| Dividend Payout % | 1% | 1% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % | 
| 5 Years: | % | 
| 3 Years: | % | 
| TTM: | 3% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % | 
| 5 Years: | % | 
| 3 Years: | % | 
| TTM: | -28% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% | 
| 5 Years: | 26% | 
| 3 Years: | 14% | 
| 1 Year: | -26% | 
| Return on Equity | |
|---|---|
| 10 Years: | % | 
| 5 Years: | % | 
| 3 Years: | % | 
| Last Year: | 12% | 
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 10 | 10 | 
| Reserves | 523 | 591 | 
| 333 | 336 | |
| 227 | 232 | |
| Total Liabilities | 1,093 | 1,169 | 
| 159 | 506 | |
| CWIP | 307 | 22 | 
| Investments | 2 | 2 | 
| 625 | 640 | |
| Total Assets | 1,093 | 1,169 | 
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -7 | 123 | |
| -102 | -71 | |
| 82 | -37 | |
| Net Cash Flow | -27 | 15 | 
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 149 | 140 | 
| Inventory Days | 188 | 211 | 
| Days Payable | 156 | 155 | 
| Cash Conversion Cycle | 181 | 197 | 
| Working Capital Days | 97 | 93 | 
| ROCE % | 13% | 
Documents
Announcements
- 
        
          Announcement under Regulation 30 (LODR)-Newspaper Publication
          
            18 Oct - Newspaper Advertisement regarding 100 days campaign - "Saksham Niveshek" is attached herewith.
- 
        
          Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
          
            7 Oct - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025 is attached herewith
- 
        
          Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
          
            30 Sep - 41st AGM Sep 29, 2025: seven resolutions passed; final dividend Re.0.10/share; consolidated scrutinizer report.
- Shareholder Meeting / Postal Ballot-Outcome of AGM 29 Sep
- 
        
          Closure of Trading Window
          
            26 Sep - Trading window closed Oct 1, 2025 until 48 hours after unaudited results for quarter/H1 ended Sep 30, 2025.
Annual reports
- 
    
      Financial Year 2025
      from bse
- 
    
      Financial Year 2024
      from bse
- 
    
      Financial Year 2023
      from bse
- 
    
      Financial Year 2022
      from bse
- 
    
      Financial Year 2021
      from bse
- 
    
      Financial Year 2020
      from bse
- 
    
      Financial Year 2019
      from bse
- 
    
      Financial Year 2018
      from bse
- 
    
      Financial Year 2017
      from bse
- 
    
      Financial Year 2016
      from bse
- 
    
      Financial Year 2015
      from bse
- 
    
      Financial Year 2014
      from bse
- 
    
      Financial Year 2013
      from bse
- 
    
      Financial Year 2012
      from nse
- 
    
      Financial Year 2012
      from bse
Concalls
- 
      Aug 2025Transcript PPT
- 
      Jun 2025Transcript PPT
- 
      May 2025TranscriptNotesPPTREC
- 
      Feb 2025Transcript PPT
- 
      Nov 2024Transcript PPT REC
- 
      Aug 2024Transcript PPT REC
- 
      Jun 2024TranscriptPPT
- 
      May 2024TranscriptPPT
- 
      May 2024Transcript PPT
- 
      Feb 2024Transcript PPT REC
- 
      Nov 2023Transcript PPT REC
- 
      Aug 2023Transcript PPT
- 
      May 2023Transcript PPT
- 
      Feb 2023TranscriptPPT
- 
      Nov 2022Transcript PPT
- 
      Aug 2022Transcript PPT
- 
      May 2022TranscriptPPT
- 
      Feb 2022TranscriptPPT
- 
      Nov 2021Transcript PPT
- 
      Aug 2021TranscriptPPT
- 
      Jun 2021Transcript PPT
- 
      Nov 2020TranscriptNotesPPT
Business Segments
1) Domestic Branded Business: The company develops pharmaceutical formulations in various forms, including injectables, syrups, ointments, lotions, and herbal products. It serves 15+ therapeutic areas, including critical care, infertility, nutraceuticals, etc with a portfolio of 100+ products, 200+ SKUs, and a network of 30,000+ prescribers. It is one of the largest manufacturers of Lyophilized Injections in India. The company aims to expand into Biologicals and Immuno-Oncology. [1] [2]